Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 20Breast 3Head & Neck 2Other 1

Conditions

Breast Neoplasms 3Sexual Dysfunctions, Psychological 1Breast Neoplasms, Male 1

Interventions

Fulvestrant 81Letrozole 74Paclitaxel 71pembrolizumab 67Specimen Handling 63Trastuzumab 60Carboplatin 55Magnetic Resonance Spectroscopy 50ribociclib 47Capecitabine 47Anastrozole 45palbociclib 44pertuzumab 43Tamoxifen 38Cyclophosphamide 38exemestane 37abemaciclib 37Biopsy 35trastuzumab deruxtecan 30Docetaxel 28Taxes 27Gemcitabine 25Radiotherapy 24Surveys and Questionnaires 23130-nm albumin-bound paclitaxel 23Standard of Care 21Blood Specimen Collection 21sacituzumab govitecan 20olaparib 20eribulin 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leuprolide × Breast × 90 days × Clear all
NCT05827081 2026-06-03

Adjuvant WIDER

Novartis

Phase 3 Recruiting
1,400 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

NCT04569747 2026-04-02

ADEPT

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
393 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡